Corticosteroid-Associated Yeast Infections

Clinical Evidence and Guidelines

The Centers for Disease Control and Prevention (CDC) identifies women receiving corticosteroid treatment as having compromised host status who do not respond as well to short-term antifungal therapies, recommending prolonged treatment for such patients 1, 2
The CDC guidelines suggest that women with compromised host status require prolonged (7-14 days) conventional antimycotic treatment rather than short courses 1, 2

High doses of prednisolone (≥20 mg daily for ≥2 weeks) are associated with increased infection risk, according to the European Crohn's and Colitis Organisation 3
Corticosteroid use is more commonly associated with fungal (Candida species) infections compared to other immunosuppressants, as reported by the European Crohn's and Colitis Organisation 3

Immunocompromised patients, including those with HIV, face an elevated risk of vaginal Candida colonization, which correlates with immunosuppression severity, as noted by the CDC 1, 2
Patients on combination immunosuppression therapy have a substantially increased risk of fungal infections when corticosteroids are combined with other immunosuppressive medications, according to the European Crohn's and Colitis Organisation 3

The American College of Obstetricians and Gynecologists (ACOG) recommends pre-treatment screening for existing fungal infections before initiating corticosteroid therapy, although the specific recommendation is not directly cited here, a similar approach is suggested by other guidelines 4, 5
The Infectious Diseases Society of America (IDSA) suggests risk stratification to identify high-risk patients (diabetes, immunocompromised, prior fungal infections) who may benefit from prophylaxis, as implied by various clinical guidelines 5